Evolus (NASDAQ:EOLS) Lowered to “Neutral” at Mizuho

Mizuho lowered shares of Evolus (NASDAQ:EOLS) from a buy rating to a neutral rating in a research report released on Tuesday, AnalystRatings.com reports. They currently have $3.00 price target on the stock, down from their previous price target of $8.00.

A number of other equities research analysts have also weighed in on EOLS. HC Wainwright lowered their price objective on Evolus from $15.00 to $7.00 and set a buy rating on the stock in a report on Tuesday. Wells Fargo & Co lowered their price objective on Evolus from $10.00 to $5.00 and set an equal weight rating on the stock in a report on Thursday, April 30th. Barclays reduced their price target on shares of Evolus from $9.00 to $4.00 and set an underweight rating for the company in a research report on Wednesday, May 13th. SunTrust Banks reduced their price target on shares of Evolus from $18.00 to $12.00 and set a buy rating for the company in a research report on Tuesday, May 12th. Finally, Stifel Nicolaus reduced their price target on shares of Evolus from $30.00 to $25.00 and set a buy rating for the company in a research report on Thursday, April 16th. Two analysts have rated the stock with a sell rating, three have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $11.88.

Shares of EOLS opened at $3.86 on Tuesday. Evolus has a twelve month low of $3.08 and a twelve month high of $20.27. The stock’s 50 day moving average is $5.08 and its two-hundred day moving average is $6.99. The firm has a market capitalization of $179.43 million, a PE ratio of -1.13 and a beta of 3.19. The company has a current ratio of 5.58, a quick ratio of 5.02 and a debt-to-equity ratio of 1.24.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.75) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.03). Evolus had a negative net margin of 217.51% and a negative return on equity of 197.30%. The business had revenue of $10.50 million during the quarter, compared to analysts’ expectations of $16.91 million. On average, sell-side analysts predict that Evolus will post -2.68 EPS for the current year.

Several institutional investors have recently modified their holdings of the stock. Tang Capital Management LLC raised its position in shares of Evolus by 25.0% during the 1st quarter. Tang Capital Management LLC now owns 3,295,000 shares of the company’s stock worth $13,674,000 after purchasing an additional 660,000 shares during the last quarter. MFN Partners Management LP raised its position in shares of Evolus by 1,083.3% during the 1st quarter. MFN Partners Management LP now owns 1,420,000 shares of the company’s stock worth $5,893,000 after purchasing an additional 1,300,000 shares during the last quarter. Stonepine Capital Management LLC raised its position in shares of Evolus by 108.4% during the 1st quarter. Stonepine Capital Management LLC now owns 822,960 shares of the company’s stock worth $3,415,000 after purchasing an additional 428,070 shares during the last quarter. EcoR1 Capital LLC acquired a new position in shares of Evolus during the 4th quarter worth approximately $7,302,000. Finally, Sphera Funds Management LTD. raised its position in shares of Evolus by 266.7% during the 1st quarter. Sphera Funds Management LTD. now owns 550,000 shares of the company’s stock worth $2,283,000 after purchasing an additional 400,000 shares during the last quarter. Hedge funds and other institutional investors own 42.43% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Further Reading: How is the discount rate different from the Federal Funds rate?

Analyst Recommendations for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.